We are delighted to announce that Bryan Murphy-Eustis, MBA, MPH, is joining The Max Foundation’s Executive Team as Vice President of Programs.
Bryan joins the team with more than 18 years of experience building and leading high-impact mission-driven teams, most recently as Commercialization Lead for Medical Technologies at Global Good at Intellectual Ventures. Previously he served as Executive Director of PIH Liberia and Chief Operating Officer of Ebola Responses at Partners in Health, where he led clinical and operational teams that rapidly initiated and scaled services to 20 treatment facilities across two countries.
“It’s an incredible privilege to be joining The Max Foundation,” says Bryan. “That so many people are still prohibited from accessing live-saving medication is a grave injustice. I’ve long been familiar with The Max Foundation’s amazing work and I am honored to support such a vital effort toward increasing access to care.”
The Max Foundation CEO, Pat Garcia-Gonzalez, notes: “We added the VP of Programs position at our organization to reflect our growing commitment to patients and the long-term sustainability of our programs. As someone deeply committed to mission and impact and with a strong background in operations, Bryan fits right in. I look forward to working closely with Bryan to develop our potential towards a vision where all people can face cancer with dignity and hope.”
We’re excited about Bryan’s invaluable experience to help us shape a new decade of growth and impact for bridging access to treatment and care for people facing cancer worldwide.
Please join us in welcoming Bryan to The Max Foundation team!
The Max Foundation (Max) is a global health nonprofit organization dedicated to accelerating health equity. For more than 25 years, Max has pioneered practical, scalable, high-quality solutions to bring lifesaving treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope. Learn more at www.themaxfoundation.org
Today, Spot On CML is active in 19 countries and, on June 29th, 17 patients were chosen by the treating physicians at Philippine General Hospital to take part in the program. While CML testing is available in the Philippines, it’s prohibitively expensive – placing critical diagnostic information out of reach for many patients.
We are delighted to announce that John Menapace has joined the Max Foundation as CFO/VP of Administration. John brings demonstrated business leadership to his new role with a background comprising more than 20 years of experience in driving growth and profitability, across Fortune 50, Big 5, non-profit, and start-up companies. His prior roles include positions….
February 21, 2018 · The Max Foundation and Dr. Jerry Radich of the Fred Hutchinson Cancer Research Center are partnering to help tackle the problem of access to accurate tests for chronic myeloid leukemia (CML) diagnostics in low- and middle-income countries through Spot On CML. Spot On CML is a low-cost, paper-based diagnostic testing method for CML, developed by Dr. Radich’s lab at Fred Hutch. Through a Spot On CML test, a physician spots a patient’s blood onto a paper test card and sends it to Dr. Radich’s lab for processing, where they perform accurate diagnostic testing on the samples even after weeks of transport. Once patients are diagnosed, The Max Foundation connects them with available treatments free of charge.
